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Abstract
Background: Allogeneic and autologous haematopoietic stem cell transplantation are established treatment
options for haematological malignancies and may possibly be employed to treat a range of genetic and
autoimmune diseases.
Case presentation: We report two patients who developed an acute myelitis within their thoracic spinal cord after
allogeneic stem cell transplantation. Myelitis in these patients was not related to graft versus host disease or
immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.
Conclusions: Myelitis is a possibly disabling consequence of haematopoietic stem cell transplantation.
Background
Autologous and allogeneic haematopoietic stem cell
transplantation (HSCT) are increasingly employed in the
treatment of haematological malignancies and solid
tumors. Allogeneic HSCT requires eradication of the
patients bone marrow by high dose combination che-
motherapy and total body irradiation and intravenous
injection of stem cells isolated from the bone marrow or
the blood of a related or unrelated human leukocyte
antigen (HLA)- identical donor. After HSCT, immuno-
suppressive treatment is required to reduce the risk of
transplant rejection and graft versus host disease
(GvHD) [1].
Neurological complications after HSCT include meta-
bolic encephalopathies, cerebral infarctions, bleedings and
infections due to bone marrow depletion or immuno-
suppression. GvHD which develops in 40-70% of patients
after allogeneic HSCT may manifest as polyneuropathy,
myositis or myasthenia [1,2]. We report two patients who
developed acute myelitis after allogeneic HSCT indicating
that myelitis should be included in the list of possible neu-
rological complications of HSCT.
Case Presentation
Case 1
A 57 year old male Caucasian was diagnosed with
chronic myelo-monocytic leukaemia in April 2004. He
was treated with hydroxycarbamide until April 2005
before an allogeneic unrelated peripheral stem cell
transplantation was performed. During this procedure,
he was treated with 40 mg/m
2 fludarabine and 130 mg/
m
2 busulfan on day -6 to -3 [3]. GvHD prophylaxis was
achieved with 20 mg/m
2 anti-thymocyte-globulin on day
-3 to -1, 5 mg/m
2 methotrexate and tacrolimus (serum
concentration 10 ng/ml). He did not show any signs of
GvHD.
Four weeks after stem cell transplantation, he devel-
oped an acute numbness of both feet, weakness of his
lower extremities and urinary difficulties and was
admitted to our hospital. On admission, he had a mild
paraparesis (MRC grade 4 in both legs) but was still
able to walk. He had hypaesthesia and paraesthesia in
both legs with a cranial level at L1 and difficulty
urinating.
Magnetic resonance imaging (MRI) of the spinal cord
showed a hyperintense lesion on T2-weighted images
extending from the T5 to the T10 thoracic vertebral
body which was not contrast enhancing (Figure 1a, b).
Cerebral MRI did not show any hyperintense lesions on
T2- or FLAIR-weighted images and no contrast
enhancement. Cerebrospinal fluid (CSF) analysis
revealed an increased protein concentration, normal cell
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negative for CMV, HSV-1, HSV-2, VZV, HHV-6 and
HHV-7 DNA. Flow cytometric analysis of peripheral
blood cells was normal and without evidence for recur-
rence of leukaemia. Based on these findings, a diagnosis
of acute myelitis was made and the patient was treated
with 500 mg methylprednisolone i.v. per day for five
days. Within the following weeks, the symptoms resolved
except for a hypoesthesia in both feet. Immuno-
suppressive treatment with Tacrolimus was switched to
cyclosporin (serum concentration 200 ng/ml) and
stopped after two weeks. After that, the neurological
status of the patient remained constant for 1 ½ years.
The patient was admitted again in February 2006 with
a new weakness and numbness in his legs. On exami-
nation, he had a mild paraparesis (MRC grade 4), his
knee and ankle reflexes were brisk and plantar
responses were normal. He had hypaesthesia of his
legs and trunk with a cranial level at Th12. He was
able to stand independently and walk a few steps with
walking aids. MRI showed a new T2 hyperintense
lesion within the spinal cord extending from the T3 to
the T5 thoracic vertebral body which was partially
contrast enhancing. Symptoms improved after i.v. treat-
ment with 1000 mg methylprednisolone per day for
5 days and tapering doses of oral prednisolone for
4 weeks. After that, he was able to walk 500 meters
with walking aids. In November 2006 the patient com-
plained again about a progressive weakness of the legs
with a walking distance of 100 meters. On examina-
tion, he had a mild paraparesis (MRC grade 4 in both
legs). Knee and ankle reflexes were exaggerated and
Babinski’s sign was positive on the left side. Sensitivity
t ol i g h tt o u c hw a sa b s e n ta n dp o s i t i o ns e n s ew a s
markedly diminished in both feet. MRI of his spinal
cord showed a new hyperintense lesion on T2-
weighted images in the cervical spinal cord at the level
of the C3 vertebral body. The patient was treated with
Figure 1 MRI data of patient 1 (a, b) and patient 2 (c, d). Saggital (a) and axial (b) T2-weighted magnetic resonance images show increased
signal intensity in the spinal cord of patient 1. The lesion extends from the T5 to the T10 vertebral body. The axial image shows the spinal cord
at the level of the T6 vertebral body. (c) T2-hyperintense lesion on the level of the C4 vertebral body of patient 2. (d) Brain-MRI shows a single
T2-hyperintense paraventricular left hemispheric lesion in patient 2.
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2 intravenous cyclophosphamide every four
weeks for seven months. During the first five infusions,
the weakness and numbness of his legs improved and
subsequently remained stable. He was able to walk 500
meters at that time. Upon repeated follow-up visits
over a period of three years, the neurological status
was stable and control MRI scans of the spinal cord
did not show any new lesions.
Case 2
A 65 year old Caucasian developed acute myeloic leukae-
mia in October 2006. Two months later, allogeneic HSCT
of a HLA-identical related donor was performed after
conditioning with 30 mg/m
2 fludarabine, 100 mg/m
2
amsacrine and 2000 mg/m
2 ara c on days -12 to -9,
40 mg/kg cyclophosphamide on days -5 and -4, 10 mg/kg
anti-thymocyte globulin on days -4 to -2 and 4 Gy total
body irradiation. He received cyclosporin and mycopheno-
lat mofetil for GVHD prophylaxis and remained in com-
plete remission during repeated follow up visits. In
September 2009, he noticed a weakness and hypoesthesia
in his left foot and a few days later in his right foot and
difficulties to urinate. Upon examination, he displayed a
mild paraparesis (hip flexion and knee extension MRC
grade 4) with normal reflexes and without pyramidal
signs. Sensitivity to pain and temperature was diminished
in both legs. MR tomography showed hyperintense lesions
on T2 weighted images within the spinal cord at the level
of the C2, C4 and T8 vertebral bodies which were partially
contrast-enhancing (Figure 1c). CSF protein concentration
was increased (55 mg/dl) and oligoclonal bands were posi-
tive. Anti-nuclear antibodies, antibodies against Borrelia
burgdorferi and PCR for CMV, HSV-1, HSV-2 and VZV-
DNA were all negative. Visually evoked potentials were
normal. After high dose i.v. methylprednisolone therapy
(1000 mg methylprednisolone per day for five consecutive
days), the symptoms resolved completely. The weakness in
both legs appeared again in October 2009. MRI showed a
T2 hyperintense, contrast enhancing left-hemispheric
lesion (Figure 1d) and contrast enhancement of the lesion
within the cervical spinal cord. The symptoms resolved
completely after high dose intravenous methylpredniso-
lone therapy.
Conclusions
According to recent publications, about 16% of patients
with autologous and allogeneic HSCT develop neurolo-
gical complications [1,2]. These complications include
drug related encephalopathies, seizures, cerebral infarc-
tions and haemorrhages that result from bone marrow
depletion and infections during immunosuppression.
Within months or years after HSCT, CNS manifesta-
tions of the original disease and secondary neoplasms
may develop.
The diagnosis of acute myelitis was based on T2
hyperintense signals in spinal cord MRI, increased CSF
protein concentration and oligoclonal bands. The fact
that no infectious agent could be identified, the respon-
siveness to i.v. methylprednisolone and the fact that the
condition recurred at different levels of the spinal cord
further support this diagnosis and rule out other diag-
noses including glioma, infarctions or viral infections of
the spinal cord. Myelitis in these patients could possibly
be a manifestation of CNS vasculitis, a heterogeneous
group of diseases that include primary CNS vasculitis
and vasculitis associated with connective tissue disease
like systemic lupus erythematodes and Behcet disease.
However, primary CNS vasculitis only rarely involves
the spinal cord and is characterized by cerebral infarcts
and irregularly configured cerebral vessels on brain
MRA. In addition, the patients did not show any sys-
temic symptoms of connective tissue disease. Myelitis as
a manifestation of CNS vasculitis is thus unlikely.
Patient 2 showed a single T2 hyperintense lesion on
cerebral MRI and in combination with the three lesions
within the spinal cord would fulfill the diagnostic cri-
teria for relapsing multiple sclerosis. However, the age
at disease onset and the apparently self limiting course
argue against this diagnosis.
One frequent complication of HSCT is acute or
chronic GvHD which most commonly affects the skin,
the intestinal mucosa and the liver. Both patients did
not show any clinical signs of GvHD indicating that
myelitis in these patients is not a manifestation of
GvHD. In addition, myelitis after HSCT could be a
result of immune reconstitution similar to the immune
reconstitution inflammatory syndrome (IRIS) that has
been well characterized in HIV infected individuals
under highly active anti-retroviral therapy but has also
been reported to occur after HSCT [4]. However, the
fact that myelitis in patient one developed years after
reestablishment of the immune system and the fact that
myelitis had a remitting course in both patients argues
against this possibility.
Alternatively, myelitis in these patients could be
caused by an immune attack of the donors HLA-identi-
cal lymphocytes against the hosts CNS-tissue and this
could indicate an inherent risk of allogeneic HSCT to
induce autoimmune phenomena. It would be important
to know whether this is indeed the case, because HSCT
is considered to be a treatment option for autoimmune
diseases including severe forms of multiple sclerosis
[5,6]. Multiple sclerosis is believed to be mediated by
self-directed lymphocytes and allogeneic HSCT offers
the advantage of replacing the endogenous autoreactive
immune cell repertoire with new, possibly less autoreac-
tive immune cells. The presented cases now indicate
that allogeneic HSCT carries the risk to induce
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sequences. The incidence of myelitis after HSCT may be
higher than previously estimated because similar cases
may not have been reported and the incidence may vary
between different ethnic groups.
These two cases demonstrate myelitis as a possible
complication of HSCT. Myelitis was not a result of
GvHD or immune reconstitution and was successfully
treated with high dose intravenous methylprednisolone
and intravenous cyclophosphamide.
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